Tag Archives: acquisition

Johnson & Johnson beats expectations despite recalls, litigation and acquisition costs

Posted on January 24, 2012 by Martin Timble

Johnson & Johnson (NYSE:JNJ) shares are trading slightly higher today after the healthcare giant posted better than expected earnings despite seeing a huge drop in profits. The company has had a year full of recalls, litigation and acquisition that seen …

Posted in Healthcare, Main Post | Tagged acquisition, analyst, earnings, healthcare, JNJ, Johnson & Johnson, litigation, NYSE, NYSE:JNJ, profits, recalls, revenue, shares, trading, Wall Street | Comments Off

Friday’s big time losers and the reasons why (MBLX, DMND, PCX)

Posted on January 13, 2012 by Martin Timble

In this report: Metabolix (NASDAQ:MBLX), Diamond Foods (NASDAQ:DMND) and Patriot Coal Corp. (NYSE:PCX)

Metabolix (NASDAQ:MBLX) shares have sank by more than 55 percent today after Archer Daniel’s Midland announced that it has terminated its joint venture with the bio-plastics maker. …

Posted in Latest Headlines, Reports | Tagged acquisition, Archer Daniel's, business, Buy, capital, Coal, deal, Department of Justice, diamond foods, DMND, downgrade, financial, Jefferies, Joint Venture, MBLX, Metabolix, NASDAQ, NASDAQ:DMND, NASDAQ:MBLX, NYSE, NYSE:PCX, partnership, Patriot Coal Corp., payments, PCX, Pringles, Procter & Gamble, production, rating, report, shares, walnut growers | Comments Off

Thursday’s big time losers and the reasons why (EK, CWTR, OCR)

Posted on January 12, 2012 by Martin Timble

In this report: Eastman Kodak (NYSE:EK), Coldwater Creek (NASDAQ:CWTR) and Omnicare (NYSE:OCR).

Eastman Kodak (NYSE:EK) volatile shares tanked by more than 18 percent today after seeing 2 days of rallying after the company announced that it had filed a patent …

Posted in Latest Headlines, Reports | Tagged AAPL, acquisition, Analysts, Apple, Coldwater Creek, company, CWTR, deal, Eastman Kodak, EK, expects, Federal Trade Commision, HTC, infringement, NASDAQ, NASDAQ:AAPL, NASDAQ:CWTR, NYSE, NYSE:EK, NYSE:OCR, OCR, OmniCare, outlook, patent, PharMerica, quarter, retailer, RIM, shares, speculation, suits | Comments Off

What’s up Delta Air Lines, MGM Resorts and EMC?

Posted on January 12, 2012 by Josie Middleton

In this report: Delta Air Lines (NYSE:DAL), MGM Resorts International (NYSE:MGM) and EMC Corp. (NYSE:EMC).

Delta Air Lines (NYSE:DAL) shares are trading over 4 percent higher today after a report was released that said the company is interested in buying …

Posted in Latest Headlines, Reports | Tagged acquisition, American Airlines, AMR, Analysts, bankruptcy, buying, casino, DAL, Delta Air Lines, EMC, EMC Corp., gambling, JP Morgan, massachusetts, MGM, MGM Resorts International, NYSE, NYSE:DAL, NYSE:EMC, NYSE:MGM, rating, report, share, stock, tech, upgrade, wall street journal | Comments Off

What’s up Voxx International, Virtus Investment Partners and Capital One Financial?

Posted on January 10, 2012 by Martin Timble

In this report: Voxx International Corp. (NASDAQ:VOXX), Virtus Investment Partners (NASDAQ:VRTS) and Capital One Financial Corp. (NYSE:COF).

Voxx International Corp. (NASDAQ:VOXX) is trading over 17 percent higher today after the company reported its third quarter financials that beat analyst expectations. …

Posted in Latest Headlines, Reports | Tagged acquisition, analyst, Capital One Financial Corp., carters, COF, company, earnings, expectations, FBR, financials, income, investment, NASDAQ, NASDAQ:VOXX, NASDAQ:VRTS, NYSE, NYSE:COF, pending, quarter, report, S&P, sales, smallcap, top picks, trading, Virtus Investment Partners, VOXX, Voxx International Corp., VRTS | Comments Off

What the fuss Google, Oracle and Achillion Pharmaceuticals?

Posted on January 9, 2012 by Cameron White

In this report: Achillion Pharmaceuticals (NASDAQ:IDIX), Google (NASDAQ:GOOG) and Oracle (NASDAQ:ORCL).

Achillion Pharmaceuticals (NASDAQ:IDIX) and other Hepatitis C drug makers soared on Monday morning after Inhibitex (NASDAQ:INHX) became a $2.5 billion acquisition target for Bristol Myers Squibb (NYSE:BMY). The move, …

Posted in Latest Headlines, Reports | Tagged Achillion Pharmaceuticals, acquisition, Analysts, BMO Capital, BMY, Bristol-Myers Squibb, CEO, downgrade, drug, financial, firm, GOOG, Google, hepatitis C, IDIX, Inhibitex, investment, investors, Motorola Mobility Holdings, NASDAQ, nasdaq:goog, NASDAQ:IDIX, NASDAQ:ORCL, Oracle, ORCL, quarter, rating, report, sales, smartphone, treatments | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.